

QUININE PROPHYLAXIS INDUCED HEPATOTOXIC AND HEPATOCELLULAR EFFECTS IN ANIMAL MODEL: TARGETING MISUSE AGAINST SARS-COV-2 IN COVID-19 ERA

Moses-Otutu, I. M., Adoghe, O. P. and Odigie, E. B.*

Department of Medical Laboratory Science, School of Basic Medical Sciences, College of Medical Sciences, University of Benin, Nigeria

*Corresponding Author: GSM: +2348023345132 , bolaji.odigie@uniben.edu

ORCID ID: 0000-0002-1233-0491

Received: 14th January, 2022 Accepted: 25th April, 2022 Published: 30th June, 2022

ABSTRACT

Background: Quinine prophylaxis against SARS-CoV-2 is on the rise particularly in the face of COVID-19.

Aim: this study examines hepatic tissues and enzymes following quinine prophylaxis in animal models representing quinine abuse in COVID-19 era.

Materials and Methods: Twenty male Albino wistar rats (180-200g) were randomly picked into four groups (n=5). Rats were maintained in a clean and aerated environment and fed with standard pellets and water provided *ad libitum*. Group I served as control. While group II, III and IV were treated with quinine at concentrations of 10, 20, and 30mg/kg b.w respectively on the left thigh using 5mL syringe. Rats were treated for 28 days at two days intervals and sacrificed by cervical dislocation. Blood was collected for the assessment of the liver function from the cardiac region while liver samples were excised, grossed and fixed in 10% formalin for histology. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin were determined.

Results: Serum activities of AST, ALT, and total bilirubin in group II to IV were elevated against the untreated group 1 ($p < 0.05$). While, ALP in group II to IV reduced tremendously compared with the control ($p < 0.05$), which is strongly suggestive of hepatotoxicity. Histopathology showed hepatocellular degeneration, vacuolation, periportal inflammation and necrosis.

Conclusion: Quinine prophylaxis in animal model induced hepatotoxic effects leading to increased hepatic enzymes particularly (AST, ALT), and bilirubin with hepatocellular damages in this study. Therefore, quinine prophylaxis against SARS-CoV-2 should be discontinued except COVID-19 has been diagnosed while hepatic enzymes of patients should be monitored along treatment.

Keywords: Quinine, prophylaxis, liver enzymes and hepatocellular damages

BACKGROUND

Quinine is naturally obtained from the bark of *C. officinalis* (Achan *et al.*, 2011), which is now synthesized in the laboratory as an antimalarial prescription drug (Jomsky and Nicholas, 2020). Due to emergence of SARS-CoV-2 infection responsible for COVID-19 pandemic (WHO, 2021), many people turned to treatment using herbal preparations (Odigie *et al.* 2020b) while some opted for quinine prophylaxis with the hope that it combats the virus. Grobe *et al.*, (2021) hypothesize that quinine may exert

antiviral effects on SARS-CoV-2 and as such infected individuals may not go down with COVID-19. In Indonesia, health authorities are trialing quinine as a possible treatment for COVID-19 patients (Andriyanto, 2020). In Russia, quinine derivatives, mefloquine is undergoing clinical trials for possible intervention (Sputnik, 2020) while, an American randomized placebo-controlled study assessed the effect of a quinine-containing nasal spray in healthcare professionals (US-NLM, 2021).

Citation: Moses-Otutu, I. M., Adoghe, O. P., and Odigie, E. B.* (2022): Quinine Prophylaxis Induced Hepatotoxic and Hepatocellular Effects in Animal Model: Targeting Misuse Against Sars-Cov-2 In Covid-19 Era *BJMLS*. 7(1):16 - 21

Quinine has reportedly been used to treat viruses and has been demonstrated in-vitro against dengue (Marois *et al.*, 2014), herpes simplex, and influenza A. viruses (Malakar *et al.*, 2018). Effects of quinine on hepatic tissues and enzymes function is paramount and should not be overlooked. We should be mindful of the liver function while on prophylaxis against SARS-CoV-2, as it is the processing house for major metabolic activities in vertebrates (Grobe *et al.*, 2021). From the foregoing, there is limited information on quinine prophylaxis against SARS-CoV-2 particularly as new strains keep re-emerging by the day. SARS-CoV-2 which is the causative agent has not been experimented in this study rather, the use of quinine as prevention regimen is our primary concerns. Therefore, possible outcomes like hepatocellular and hepatic enzymes effects of quinine prophylaxis in animal models were investigated.

MATERIALS AND METHODS

Description and preparation of Quinine

Quinine was obtained from a government approved pharmaceutical stores with NAFDAC Registration Number: 06-0881 while distilled water was used as vehicle in preparing the stock solution in accordance to manufacturer's instructions.

Animal Housing and Ethical Clearance

Twenty inbred male Albino wistar rats weighing (180-200g) were obtained from the animal housing facility of Anatomy Department, University of Benin, Nigeria. Animals were housed in steel wire cages and acclimatized for 14days under ambient temperature ($25\pm 3^{\circ}\text{C}$), humidity (45-55%), and periodicity (12:12hourly) prior to experimentation. Clean and aerated environment was maintained regularly by the animal house keeper. Rats were fed with standard pellets (Standard feed Nigeria Plc.) and water provided *ad libitum*. Rats were handled according to international guidelines as reported by the Institute for Laboratory Animal Research (NRC, 2011). Ethical clearance (V.1034/36) was obtained from

the Ministry of Agriculture and Natural Resources, Benin City; Edo State, Nigeria.

Lethal Dose Determinations (LD₅₀)

Acute toxicity study was conducted according to an existing report in the manufacturer's instruction manual for 7days. Lethal dose (LD₅₀) determination was an adaptation to Lorke's (1983) method. Three rats were used and extrapolated doses (20mg/kg b.w, 30mg/kg b.w, and 40mg/kg b.w respectively) from a previous study (Gorbes, 2021) were administered. They were monitored within the first 4hrs for mortality and other signs like restlessness, paw licking, salivation, and stretching.

Experimental Designs

The rats were caged per group (I to IV, n=5) while group I served as the control. Group II was administered 10 mg/kg b.w of quinine, group III 20mg/kg b.w and group IV 30mg/kg b.w. Each rat was picked with a hand towel while 5mL syringe / needle gauge was used to inject the dosages on the left thigh to ensure adequate deliveries. They were weighed before and after experimentation and treated for twenty-eight (28) days, at 2 days interval. The animals were decapitated using cervical dislocation after experimentation. They were incised from the chest wall to the stomach while 4mL of whole blood was collected by retro-orbital puncture from the medial canthus into plain tubes and centrifuged (BROADBENT, UK) at 3000 rpm for 5 minutes to obtain the serum for liver function tests (ALT, AST, ALP and bilirubin). Liver were excised, washed in normal saline and cut in slabs of about 5mm thickness before fixing in 10% formalin. They were processed according to the paraffin wax method using an automatic tissue processor. Sections were cut using rotary microtome to obtain 3 μ thickness and stained with H&E.

Photomicrography and Statistics

We examined each section with the Olympus Binocular Microscope® and photographed with a digital microscope camera (Samsung model SS850).

Results were expressed as mean±standard error of mean (SEM), and differences between values determined using ANOVA and Tukey's post hoc test, and $p < 0.05$ considered significant.

RESULTS

Quinine prophylaxis with 30mg/kg b.w showed that AST (46.13 ± 1.15 U/L), ALT (24.01 ± 0.03 U/L) and total bilirubin (0.20 ± 0.16 U/L) levels were elevated ($p < 0.05$) compared with rats on 10mg/kg [AST (41.50 ± 0.07 U/L), ALT (16.12 ± 1.15 U/L), total bilirubin (0.12 ± 0.12 U/L)] and 20mg/kg [AST (43.05 ± 0.03), ALT (19.12 ± 1.01), total bilirubin (0.15 ± 0.13)] against untreated

group 1: AST- 38.02 ± 1.03 U/L; ALT- 14.05 ± 0.12 U/L; total bilirubin- 0.10 ± 0.06 U/L. However, ALP levels reduced ($p < 0.05$) compared with control group 1 (21.36 ± 1.21 U/L). High dose treated rats (30mg/kg b.w) revealed a gross reduction in ALP (17.13 ± 0.07 U/L) compared with the 20mg/kg (19.11 ± 0.13 U/L) and 10mg/kg (20.42 ± 1.01 U/L) treatments respectively. Histopathology revealed periportal inflammation and diffused vacuolation, focal area of lymphoid aggregation, nuclei hepatocytes appearing hyperchromatic, multi-focal and diffused necrosis including hepatic granuloma (Plate 1A-D).




Plate 1: Showed control sections (A) and treated sections (B to D) with arrows pointed to pathological features earlier explained. H&E stains at x400magnification.

DISCUSSIONS

Since the advent of COVID-19 pandemic the world has been thrown into pandemonium on the way forward with new variant surfacing every other day. Health practitioners world-wide are increasingly getting overwhelmed while at a time there was a complete breakdown of major hospital work forces in most countries (Odigie *et al.*, 2020a). Despite the devastation globally, self-medication and personal intervention should never be encouraged because it often results to liver damages (Odigie *et al.*,

2020b). Recall that self-medication or personal intervention often leads to drug abuse and has been reported as one of the leading causes of liver damage globally (Atoigwe *et al.*, 2016). Also, the liver is prone to xenobiotics-induced injury because of its central role in xenobiotic metabolism and its portal location within the circulatory system (Adesanya *et al.*, 2012; Odigie and Odigie, 2015). Many drugs and chemicals often have adverse effects on the liver and lead to the distortion of liver architecture (Olurishe *et al.*, 2011).

Quinine Prophylaxis Induced Hepatotoxic

Therefore, the liver must be protected being at the receiving end while trying to metabolize drugs in its abused state (Odigie and Obaseki, 2015).

Changes in liver architecture (histology) following prophylactic treatment of quinine and liver marker enzymes are indicative of hepatocellular damages and hepatotoxicity. This report is consistent with Ajiboso (2012) that reported the effects of chloroquine and sulfadoxine on biochemical and hematological indices in an animal experimentation, which led to the conclusion that chloroquine was more hepatotoxic than other antimalarial of sulfa derivatives. Our study thus corroborated the findings in which the toxicity observed in hepatic enzymes biochemistry exerted closely related effects as those reported by Ajiboso (2012). Our study is in agreement with Odigie (2013) that demonstrated prophylactic consumption of sulfa drugs on the liver of rats. Sulfa drugs are often sold across the counter as antimalarial but were reported to have hepatocellular effects in rats. Although this study centered on quinine as against the former that dwelled on pyrimethamine / sulfadoxine combined therapy. Elevated serum ALT, AST and total bilirubin indices indicated injuries in the hepatocyte owing to cell membrane alteration that often makes the enzymes to leak from tissues to serum. Umana *et al.*, (2013) suggested that ALT and AST are sensitive hepatocellular biomarkers that points to liver distress and sometimes evaluate the degree to which the liver is damaged while elevated AST parameter may be due in part to liver injury, cardiac infarction and occasionally muscular degeneration. Ajithkumar *et al.*, (2012) earlier informed that ALT is more specific to the liver and served as a profound parameter for detecting liver injury.

Elevated serum liver enzymes may also be a pointer to liver necrosis particularly in high dose (30mg/kg b.w.) quinine treated rats while serum ALP and bilirubin levels relate to hepatic cells functionality. Decreased

serum ALP may be due to reduced bilirubin synthesis in the absence of biliary pressure but increased bilirubin observed in this study is largely from hepatic injury, which is evident via histopathology report. The exact mechanism by which quinine exerts its hepatotoxicity and hepatocellular effects has not been derived in this study. We suggest further research to unravel the why that has left a lacuna in the present research. However, Suh (2020); reported that drug induced liver injury occurs via multiple mechanisms involving various intracellular organelles with consequent disruption of intracellular calcium homeostasis, declined ATP levels and inflammation or bursting of the hepatocyte. High doses of prophylactic quinine treatment resulted to elevated activities of ALT and AST, and total bilirubin concentration. This is strongly related to the report by Sule *et al.*, (2012) stating that elevated liver enzymes may point to hepatic damages resulting from several mechanisms like toxic species induction or cellular membranes peroxidation. In this study, histology reports are in keeping with hepatocellular degeneration, which are not dissimilar to those revealed by Sule *et al.* (2012); Odigie (2013). Similar histological reports with evidences relating to cellular degenerations were observed by Buchweit *et al.* (2002) resulting from quinine exposure to rats. Authors however concluded that hepatocellular necrosis and other forms of hepatotoxic effects observed in their study were dose related (Buchweit *et al.* 2002), suggesting the reason for increased hepatocellular damages as dosage increases in this study. Recall that the more we increase the dosage, the more the damages caused by quinine treatment in rats.

CONCLUSION

AND

RECOMMENDATION

Prophylactic administration of quinine induces hepatotoxic effects in animal model in our study, leading to increased hepatic enzymes (AST, ALT and bilirubin), and hepatocellular damages.

This study agrees with existing reports on indiscriminate use of quinine. Therefore, quinine prophylaxis against SARS-CoV-2 should be discontinued. It should be

administered following diagnosis while monitoring hepatic enzymes of patients.

Conflicting Interests

No conflicts of interest declared

REFERENCES

- Achan, J., Talisuna, A.O., Erhart, A., Yeka, A., Tibenderana, J.K., Baliraine, F.N., Rosenthal, P.J. and D'Alessandro, U. (2011). Quinine, an old anti-malarial drug in a modern world: Role in the treatment of malaria. *Malaria Journal*. **10**(2):144-151.
- Adesanya, O.A., O.J., Huthman, I.O., Huthman, A.S. and Adesanya, R.A. (2012). Effects of a Single pill 3-drug combination of Lamivudine, Nevirapine and Zidovudine on Blood parameters and Liver Histology in Female Wistar Rats. *American Journal of Medicine and Medical Sciences*. **2**(4): 71-74.
- Ajiboso, S.O.O. (2012). Influence of chloroquine and sulfadoxine on biochemical and hematological indices in albino rats. *Indian Journal of Drugs and Diseases*, **1**(5):117-125.
- Ajithkumar, P., Jeganathan, N.S., Balamurugan, K. and Radha, K. (2012). Evaluation of hepatoprotective activity of Villorita cyrinoides extract (Black water clams) against paracetamol-induced hepatic injury in albino rats. *International Journal of pharmacy and biological sciences*. **2**(2): 23-127.
- Andriyanto, H. (2020). Indonesia Trials Quinine as Covid-19 Treatment. Jakarta Globe. Available online: <https://jakartaglobe.id/news/> (accessed on 29, November 2021).
- Atoigwe, B.E., Achukwu, P.U., Odigie, B.E. (2016). Histopathological effects of prophylactic consumption of *Sphenocentrum jollyanum* ethanolic root extract on select organs of male albino (*Rattus norvegicus*) rats. *Annals of International Medicine and Dental Research*. **2**(6):AT01-AT06.
- Buchweit, J.P., Ganney, P.E., Bursian, S.J. and Roth, R.A. (2002). Underlying endothoxemia Augmented Toxic responses to sulphonamides. Is there a relationship to drug idiosyncrasy? *Michigan State University Journal*. **18**: 220-234.
- Grobe, M., Ruetalo, N., Layer, M., Hu, D., Businger, R., Rheber, S., Setz, C., Rauch, P., Auth, J., Fröba, M., Brysch, E., Schindler, M. and Schubert, U. (2021). Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. *Viruses*. **13**: 647-664.
- Jomsky, M.G. and Nicholas, A.K. (2020). Could Low-Dose Quinine Prevent or Treat Coronavirus Infection? *EC Pharmacol. Toxicology Comment*. **8**: 62-64.
- Lorke, D. (1983). A new approach to practical acute toxicity testing. *Archive of Toxicology*. **54**(4):275-287.
- Malakar, S., Sreelatha, L., Dechtawewat, T., Noisakran, S., Yenchitsomanus, P.T., Chu, J.J.H. and Limjindaporn, T. (2018). Drug repurposing of quinine as antiviral against dengue virus infection. *Virus Research*. **255**: 171-178.
- Marois, I., Cloutier, A., Meunier, I., Weingart, H.M., Cantin, A.M. and Richter, M.V. (2014). Inhibition of influenza virus replication by targeting broad host cell pathways. *PLoS ONE*. **9**: e110631.
- National Research Council (2011). Guide for the Care and use of laboratory Animals: Eighth Edition. Washington, DC: The national Academies Press. Accessed: 25th June, 2018. Available at: <https://doi.org/10.17226/12910>

- Odigie, B.E. (2013). Histological effects of pre-exposure prophylactic consumption of sulfa drugs on liver and kidney of wistar rats (*Rattus norvegicus*). *IOSR Journal of Pharmacy and Biological Science*, **5**(6) 14-19.
- Odigie, B.E. and Obaseki, D.E. (2015). Therapeutic abuse of sulphonamide based drugs on histological indices of the liver and kidney of plasmodium-infested albino mice. *International Journal of Medicine and Health Development*. **20**(2):25-31.
- Odigie, B.E. and Odigie, J.O. (2015). Histopathology of Fascioliasis Infested Cattle Livers in Benin City, Nigeria. *Nigerian Journal of Life Science*. **5**(2): 74-82.
- Odigie, E.B., Airiagbonbu, B.O. and Adegboye, A.A. (2020a). Escapades of sex workers amidst lockdown: an untold navigation pathway for SARS-CoV-2 community transmission in Nigeria. *Journal of Medical Laboratory Science*. **30**(2):99-109.
- Odigie, E.B., Airiagbonbu, B.O., Ariagbonbu, N.T. and Omorodion, N.T. (2020b). Respiratory tract protective herbs may serve as palliatives in the battle against COVID-19 Pandemic. *International Journal of Basic Science and Technology*. **6**(2): 65-75.
- Olurishe, T.O., Kwanshie, H.O., Anuka, J., Muktar, H. and Biaslla, M. (2011). *Parasitology*. **31**(8):83-173.
- Sputnik News (2020). Pre-Clinical Trials Show Mefloquine Stop Coronavirus Cytopathic Effect, Russian Official Says. Available online: <https://sputniknews.com/amp/russia/202005151079316649-pre-clinical-trials-show-mefloquine-stop-coronaviruscytopathic-effect-russian-official-says/> (Accessed on 15 May 2020).
- Suh, J.I. (2020). Drug-induced liver injury. *Yeungnam University Journal of Medicine*. **37**(1): 2-12.
- Sule O.J., Godwin, J. and Nnoku I.A. (2012). Biochemical Investigation of Hepatotoxic effects of Antiretroviral Drugs on Wistar Albino Rats. *Journal of physiology and pharmacology Advances*. **2**(4): 171-175.
- Umana, U., Timbuk, J.A., Musa, S.A., Hamman, W.O., Asala, S., Hamboiu, J. and Anuka, J.A. (2013). Acute Hepatotoxicity and Nephrotoxicity Study of Orally Administered Aqueous and Ethanolic Extracts of *Carica papaya* Seeds in Adult Wistar Rats. *Asian Journal of Medical Sciences*. **5**(3): 65-70.
- United States National Library of Medicine (2021). GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel. Available at: <https://clinicaltrials.gov/ct2/show/NC/T04408183> (Accessed: October 30, 2021).
- World Health Organization (2021). Coronavirus disease (COVID-19) outbreak situation daily report. Available at: <https://covid19.who.int/> (Accessed: December 09, 2021).